pleconaril

Pleconaril is an investigational small molecule antiviral drug from the viral capsid inhibitor class. It was developed to prevent acute asthma exacerbations and common cold symptoms in asthmatic patients exposed to picornaviruses, including rhinoviruses and enteroviruses. Pleconaril acts by binding to a hydrophobic pocket in the Viral protein 1 (VP1) of the viral capsid, causing rigidification and compression of the capsid, which prevents uncoating of viral RNA or attachment to host cells. This inhibits viral replication and infection. Despite promising results in clinical trials for reducing duration and severity of colds due to picornaviruses, pleconaril has not been approved by the FDA due to concerns about CYP3A enzyme induction leading to potential drug interactions[1][2][3][4][6].

Brand names

Picovir

Other names

pleconaril153168-05-9